OptimizeRx (OPRX) Cash & Current Investments (2010 - 2026)

OptimizeRx has reported Cash & Current Investments for 17 years, with the latest figure at $20.2 million in Q1 2026.

• Quarterly Cash & Current Investments rose 21.7% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.2 million (up 21.7% YoY) and the FY2025 annual result came in at $23.4 million, up 74.63% from the prior year.
• Cash & Current Investments retreated to $20.2 million in Q1 2026 per OPRX's latest filing, from $23.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $89.0 million in Q1 2022 and troughed at $13.4 million in Q4 2024.
• A 5-year average of $41.1 million and a median of $20.2 million in 2026 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments plunged 81.32% in 2023, then soared 74.63% in 2025.
• Over 5 years, Cash & Current Investments stood at $74.1 million in 2022, then slumped by 81.32% to $13.9 million in 2023, then declined by 3.41% to $13.4 million in 2024, then jumped by 74.63% to $23.4 million in 2025, then retreated by 13.68% to $20.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $20.2 million, $23.4 million, and $19.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.